Aducanumab

Pic:getty/kotofeja

New Alzheimer’s treatment buoyed by US Fast Track Designation

By Rachel Arthur

Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβO) – offers the promise of an effective treatment with a better safety profile than other Alzheimer's...

Dementia research lags behind the disease burden, says the WHO report. Pic: getty/nopparit

How can dementia drug development be improved?

By Rachel Arthur

The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers